Takeda Pharmaceutical Co Ltd (TKPHF) Gross Margin (2017 - 2026)
Takeda Pharmaceutical (TKPHF) posted quarterly Gross Margin of 66.66% for Q2 2026, down 397.0% year-over-year from 22.45% in Q2 2025, and little changed quarter-over-quarter from 66.66% in Q1 2026.
Takeda Pharmaceutical Co Ltd (TKPHF) Gross Margin (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Gross Margin history runs 10 years deep, the most recent figure standing at 66.66% for Q2 2026.
- In Q2 2026, Gross Margin fell 397.0% year-over-year to 66.66%; the TTM figure through Jun 2026 stood at 65.77% (down 101.0% YoY), while the FY2026 annual figure was 18.05%, up 13.0% from the prior year.
- Gross Margin for Q2 2026 stood at 66.66%, roughly flat from 66.66% in the prior quarter.
- The five-year high for Gross Margin was 213.21% in Q3 2022, with the low at 58.95% in Q4 2022.
- The 5-year median for Gross Margin is 66.66% (2026), against an average of 74.66%.
- The sharpest annual moves came in 2022 and 2023: Gross Margin surged 14585 bps in 2022, then slumped 14571 bps in 2023.
- Takeda Pharmaceutical's Gross Margin stood at 58.95% in 2022, then gained by 8 bps to 63.6% in 2023, then grew by 0 bps to 63.73% in 2024, then fell by 1 bps to 62.93% in 2025, then increased by 6 bps to 66.66% in 2026.
- Business Quant data shows TKPHF's Gross Margin at 66.66% in Q2 2026, 66.66% in Q1 2026, and 62.93% in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.66% |
| Mar 31, 2026 | 66.66% |
| Dec 31, 2025 | 62.93% |
| Sep 30, 2025 | 66.04% |
| Jun 30, 2025 | 70.63% |
| Mar 31, 2025 | 67.96% |
| Dec 31, 2024 | 63.73% |
| Sep 30, 2024 | 66.04% |
| Jun 30, 2024 | 64.71% |
| Mar 31, 2024 | 67.96% |
| Dec 31, 2023 | 63.60% |
| Sep 30, 2023 | 67.50% |
| Jun 30, 2023 | 66.08% |
| Mar 31, 2023 | 69.67% |
| Dec 31, 2022 | 58.95% |
| Sep 30, 2022 | 213.21% |
| Jun 30, 2022 | 71.66% |
| Mar 31, 2022 | 69.88% |
| Dec 31, 2021 | 68.78% |
| Sep 30, 2021 | 67.35% |